Biocon Biologics signs MoU with CSSC in Tanzania for Mission 10 cents, affordable insulins programme Read more
Biocon Biologics to get Rs 225 cr from Tata Capital Growth Fund for 0.85 per cent equity stake Read more
Biocon and Voluntis deal to transform insulin biosimilars personalised care through digital therapeutics: GlobalData Read more
Biocon Biologics gets DCGI approval for emergency use of CytoSorb to treat critical COVID-19 patients Read more